| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (NCT05480865) | Navire Pharma Inc., a BridgeBio company | 2022-07-06 |
| An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors (NCT05481502) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-06-08 |
| Universal Germline Testing in the Community (NCT05416710) | Invitae Corporation | 2022-06-01 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (NCT05359445) | Immatics Biotechnologies GmbH | 2022-05-19 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (NCT05346484) | Imugene Limited | 2022-05-17 |
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (NCT05307874) | ImCheck Therapeutics, an Ipsen company | 2022-05-04 |
| Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (NCT05309187) | Immune-Onc Therapeutics | 2022-04-11 |
| HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy (NCT05322720) | Taizhou EOC Pharma Co., Ltd. | 2022-04-01 |
| A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations (NCT05242822) | Kinnate Biopharma | 2022-03-29 |
| TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors (NCT04976218) | Chinese PLA General Hospital | 2022-03-15 |
| COAST Therapy in Advanced Solid Tumors and Prostate Cancer (NCT05036226) | Medical University of South Carolina | 2022-03-03 |
| Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy (NCT05223608) | Centre Oscar Lambret | 2022-03-03 |
| Phase 1 First-in-human Study of JS014 (NCT05296772) | Anwita Biosciences | 2022-02-28 |
| 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors (NCT05099536) | 3D Medicines (Beijing) Co., Ltd. | 2022-02-24 |
| Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors (NCT05388487) | HighField Biopharmaceuticals Corporation | 2022-02-16 |
| Stratification of Patients in Oncogeriatrics and Personalization of Interventions (NCT05131113) | Biogipuzkoa Health Research Institute | 2022-01-27 |
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors (NCT05074472) | ZielBio, Inc. | 2022-01-14 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (NCT05216432) | Relay Therapeutics, Inc. | 2021-12-08 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology (NCT04899505) | Institut Curie | 2021-10-21 |
| FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05069935) | Fate Therapeutics | 2021-10-15 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma (NCT05078593) | Shanghai Henlius Biotech | 2021-10-11 |
| First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (NCT05054348) | Immune-Onc Therapeutics | 2021-09-30 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer (NCT04946864) | Ascentage Pharma Group Inc. | 2021-08-13 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression (NCT04927663) | Rahul Aggarwal | 2021-08-10 |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285) | Pierre Fabre Medicament | 2021-08-04 |
| Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors (NCT04989010) | Wuxi No. 4 People's Hospital | 2021-08-01 |
| Safety Study of 89Zr-NY001 PET Imaging in Patients (NCT04971369) | Wuxi No. 4 People's Hospital | 2021-08-01 |
| Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors (NCT04901806) | Pyramid Biosciences | 2021-07-20 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma (NCT04983810) | Cyclacel Pharmaceuticals, Inc. | 2021-07-12 |
| New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer (NCT05117177) | iTeos Therapeutics | 2021-07-01 |
| Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values (NCT04942717) | Memorial Sloan Kettering Cancer Center | 2021-06-18 |
| Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04902872) | Cybrexa Therapeutics | 2021-05-03 |
| CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours (NCT05518799) | The Netherlands Cancer Institute | 2021-04-22 |
| A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04859777) | Monopteros Therapeutics Inc. | 2021-04-13 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (NCT03915678) | Institut Bergonié | 2021-03-31 |
| A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (NCT04673942) | EpicentRx, Inc. | 2021-03-29 |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (NCT04665206) | Vivace Therapeutics, Inc | 2021-03-24 |
| A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors (NCT04761198) | Mereo BioPharma | 2021-03-23 |
| A Study of of HOT1030 in Patients With Advanced Solid Tumors (NCT05060263) | Huabo Biopharm Co., Ltd. | 2021-03-12 |
| NeoTIL in Advanced Solid Tumors (NCT04643574) | Centre Hospitalier Universitaire Vaudois | 2021-03-09 |
| Pembrolizumab And Lenvatinib In Leptomeningeal Metastases (NCT04729348) | Massachusetts General Hospital | 2021-03-08 |
| 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors (NCT04977128) | Wuxi No. 4 People's Hospital | 2021-03-01 |
| A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. (NCT05230186) | TScan Therapeutics, Inc. | 2021-02-26 |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib (NCT04814667) | Centre Leon Berard | 2021-02-23 |
| Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients. (NCT04739696) | University of Colorado, Denver | 2021-02-05 |
| Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (NCT04803318) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors (NCT04842812) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| Study of HL-085 in Patients With Advanced Solid Tumor Tumors (NCT04683354) | Kechow Pharma, Inc. | 2020-12-23 |
| First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) (NCT04725474) | CatalYm GmbH | 2020-12-09 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451) | Bellicum Pharmaceuticals | 2020-12-07 |
| Study on Skin Toxicities Induced by Cancer Treatments (NCT04402606) | Institut Curie | 2020-11-25 |
| Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs (NCT04770207) | Second Affiliated Hospital of Guangzhou Medical University | 2020-11-01 |
| A Study of AK112 for Advanced Solid Tumors (NCT04597541) | Akeso | 2020-10-21 |
| EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) (NCT04515043) | Invectys | 2020-10-16 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors (NCT04585035) | InventisBio Co., Ltd | 2020-10-02 |
| Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies (NCT04552288) | Memorial Sloan Kettering Cancer Center | 2020-09-16 |
| FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT04551885) | Fate Therapeutics | 2020-09-07 |
| HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma (NCT04353375) | Hutchmed | 2020-09-03 |
| A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer (NCT04474470) | TyrNovo Ltd. | 2020-09-03 |
| Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (NCT04121442) | Buzzard Pharmaceuticals | 2020-09-01 |
| Systematic Evaluation of Human Explant Model Systems Engineering (NCT04671654) | University Hospital Heidelberg | 2020-08-01 |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors (NCT04556669) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-08-01 |
| A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. (NCT04428086) | Jiangsu HengRui Medicine Co., Ltd. | 2020-07-27 |
| Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS) (NCT05252975) | Royal Marsden NHS Foundation Trust | 2020-07-01 |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04219254) | BioInvent International AB | 2020-06-29 |
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (NCT04443088) | Shenzhen Ionova Life Sciences Co., Ltd. | 2020-06-26 |
| Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study (NCT04811781) | Istituto Oncologico Veneto IRCCS | 2020-06-04 |
| Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors (NCT04504942) | CytoDyn, Inc. | 2020-05-01 |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (NCT04306900) | Trishula Therapeutics, Inc. | 2020-03-30 |
| First-in-Human Study of ICT01 in Patients With Advanced Cancer (NCT04243499) | ImCheck Therapeutics, an Ipsen company | 2020-03-05 |
| Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status (NCT04169178) | Henlix, Inc | 2020-03-03 |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (NCT04328844) | iOnctura | 2020-02-25 |
| Impact of ICU on the Quality of Life in Cancer Patients (NCT04310033) | University Hospital, Grenoble | 2020-02-24 |
| PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors (NCT03706274) | CytomX Therapeutics | 2020-01-01 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors (NCT04165772) | Memorial Sloan Kettering Cancer Center | 2019-12-11 |
| Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safety Among Cancer Patients in Malaysia (NCT04175899) | Ministry of Health, Malaysia | 2019-12-10 |
| A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (NCT04105335) | Mina Alpha Limited | 2019-11-13 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (NCT04092673) | Effector Therapeutics | 2019-10-25 |
| Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab (NCT04130516) | Linnaeus Therapeutics, Inc. | 2019-10-21 |
| Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors (NCT04041310) | Nouscom SRL | 2019-10-21 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (NCT04165330) | Sarcoma Oncology Research Center, LLC | 2019-10-17 |
| Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit (NCT03977766) | Institut Paoli-Calmettes | 2019-10-15 |
| Safety and Efficacy Study of IMSA101 in Refractory Malignancies (NCT04020185) | ImmuneSensor Therapeutics Inc. | 2019-09-23 |
| Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors (NCT03992326) | Centre Hospitalier Universitaire Vaudois | 2019-09-01 |
| A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies (NCT04014257) | Handok Inc. | 2019-08-09 |
| The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol (NCT03892018) | Athenex, Inc. | 2019-08-05 |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors (NCT04053673) | Ribon Therapeutics, Inc. | 2019-08-01 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| Study of FCN-437c in Patients With Advanced Solid Tumors (NCT03951116) | Fochon Pharmaceuticals, Ltd. | 2019-06-25 |
| Phase I Study of HL-085 in Patients With Advanced Solid Tumors (NCT03976050) | Shanghai Kechow Pharma, Inc. | 2019-06-17 |
| Phase 1a Study to Evaluate Immunogenicity of ASV® (NCT03673020) | Agenus Inc. | 2019-05-16 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124) | Immatics US, Inc. | 2019-05-14 |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies (NCT03922204) | Merus B.V. | 2019-05-08 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 (NCT03441100) | Immatics US, Inc. | 2019-05-02 |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca (NCT03919292) | Virginia Commonwealth University | 2019-05-01 |
| A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours (NCT03990233) | OSE Immunotherapeutics | 2019-04-16 |